[{"data":1,"prerenderedAt":327},["ShallowReactive",2],{"drug-famotidine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":162,"warnings":172,"renal":187,"monitoring":197,"interactions":198,"review":199,"examples":202,"atc":238,"iran":240,"links":268,"populations":288,"usApproval":322},"famotidine",1,{"fa":7,"en":8},"فاموتیدین","Famotidine","alimentary-metabolism",{"fa":11,"en":12},"آنتاگونیست گیرنده H2","H2-receptor antagonist",[14],{"name":15,"market":16},"Pepcid","US",[18,19],"famotidin","پپسید",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"susp-40-5","suspension","oral","40 mg \u002F 5 mL (8 mg\u002FmL)",{"amount":27,"unit":28,"perVolumeMl":29},40,"mg",5,[16],[32],{"source":33,"section":34},"fda-famotidine-susp","3",[36,58,73,93,114,131,145],{"id":37,"disease":38,"label":39,"population":42,"type":47,"unit":28,"dose":48,"refs":50,"limits":53,"durationDays":56},"pud","peptic-ulcer-disease",{"fa":40,"en":41},"زخم پپتیک — ۰٫۵ mg\u002Fkg یک‌بار در روز (تا ۱ mg\u002Fkg)","Peptic ulcer — 0.5 mg\u002Fkg once daily (up to 1 mg\u002Fkg)",{"minAge":43,"maxAge":45},{"value":5,"unit":44},"year",{"value":46,"unit":44},17,"weightBased",{"perKgPerDay":49,"perKgPerDayMax":5,"dividedDoses":5},0.5,[51],{"source":33,"section":52},"2.2, Table 2",{"maxPerDay":27,"refs":54},[55],{"source":33,"section":52},{"min":57,"max":57},56,{"id":59,"disease":38,"label":60,"population":63,"type":47,"unit":28,"dose":66,"refs":68,"limits":70},"pud-bid",{"fa":61,"en":62},"زخم پپتیک — ۰٫۲۵ mg\u002Fkg دو بار در روز (تا ۰٫۵ mg\u002Fkg)","Peptic ulcer — 0.25 mg\u002Fkg twice daily (up to 0.5 mg\u002Fkg)",{"minAge":64,"maxAge":65},{"value":5,"unit":44},{"value":46,"unit":44},{"perKgPerDay":49,"perKgPerDayMax":5,"dividedDoses":67},2,[69],{"source":33,"section":52},{"maxPerDay":27,"refs":71},[72],{"source":33,"section":52},{"id":74,"disease":75,"label":76,"population":79,"type":47,"unit":28,"dose":83,"refs":84,"notes":86},"gerd-neonate","gerd",{"fa":77,"en":78},"ریفلاکس — تولد تا کمتر از ۳ ماه: ۰٫۵ mg\u002Fkg یک‌بار در روز (تا ۱ mg\u002Fkg)","GERD — birth to \u003C3 months: 0.5 mg\u002Fkg once daily (up to 1 mg\u002Fkg)",{"maxAge":80},{"value":81,"unit":82},3,"month",{"perKgPerDay":49,"perKgPerDayMax":5,"dividedDoses":5},[85],{"source":33,"section":52},[87],{"text":88,"refs":91},{"fa":89,"en":90},"همراه اقدامات محافظه‌کارانه (مثل غلیظ کردن شیر). پس از ۴ هفته ارزیابی مجدد.","Use conservative measures (e.g. thickened feedings) concurrently; re-evaluate after 4 weeks.",[92],{"source":33,"section":52},{"id":94,"disease":75,"label":95,"population":98,"type":47,"unit":28,"dose":101,"refs":102,"limits":104,"notes":107},"gerd-infant",{"fa":96,"en":97},"ریفلاکس — ۳ ماه تا کمتر از ۱ سال: ۰٫۵ mg\u002Fkg دو بار در روز (تا ۱ mg\u002Fkg)","GERD — 3 months to \u003C1 year: 0.5 mg\u002Fkg twice daily (up to 1 mg\u002Fkg)",{"minAge":99,"maxAge":100},{"value":81,"unit":82},{"value":5,"unit":44},{"perKgPerDay":5,"perKgPerDayMax":67,"dividedDoses":67},[103],{"source":33,"section":52},{"maxPerDay":27,"refs":105},[106],{"source":33,"section":52},[108],{"text":109,"refs":112},{"fa":110,"en":111},"همراه اقدامات محافظه‌کارانه؛ پس از ۴ هفته ارزیابی مجدد.","Use conservative measures concurrently; re-evaluate after 4 weeks.",[113],{"source":33,"section":52},{"id":115,"disease":75,"label":116,"population":119,"type":47,"unit":28,"dose":122,"refs":123,"limits":125,"durationDays":128},"gerd-child",{"fa":117,"en":118},"ریفلاکس با یا بدون ازوفاژیت — ۱ تا کمتر از ۱۷ سال: ۰٫۵ mg\u002Fkg دو بار در روز","GERD ± esophagitis — 1 to \u003C17 years: 0.5 mg\u002Fkg twice daily",{"minAge":120,"maxAge":121},{"value":5,"unit":44},{"value":46,"unit":44},{"perKgPerDay":5,"dividedDoses":67},[124],{"source":33,"section":52},{"maxPerDose":27,"refs":126},[127],{"source":33,"section":52},{"min":129,"max":130},42,84,{"id":132,"disease":75,"label":133,"population":136,"type":138,"unit":28,"dose":139,"refs":141,"durationDays":144},"adult-gerd",{"fa":134,"en":135},"بزرگسال — ریفلاکس غیرفرسایشی: ۲۰ mg دو بار در روز","Adults — symptomatic nonerosive GERD: 20 mg twice daily",{"minAge":137},{"value":46,"unit":44},"fixed",{"perDose":140,"dosesPerDay":67},20,[142],{"source":33,"section":143},"2.1, Table 1",{"min":129,"max":129},{"id":146,"disease":38,"label":147,"population":150,"type":138,"unit":28,"dose":152,"refs":153,"notes":155},"adult-du",{"fa":148,"en":149},"بزرگسال — زخم اثنی‌عشر فعال: ۴۰ mg یک‌بار در روز","Adults — active duodenal ulcer: 40 mg once daily",{"minAge":151},{"value":46,"unit":44},{"perDose":27,"dosesPerDay":5},[154],{"source":33,"section":143},[156],{"text":157,"refs":160},{"fa":158,"en":159},"یا ۲۰ mg دو بار در روز؛ تا ۸ هفته.","Or 20 mg twice daily; up to 8 weeks.",[161],{"source":33,"section":143},[163],{"id":164,"severity":165,"text":166,"refs":169},"h2-hypersensitivity","block",{"fa":167,"en":168},"سابقه واکنش حساسیتی جدی به فاموتیدین یا سایر آنتاگونیست‌های H2.","History of serious hypersensitivity to famotidine or other H2-receptor antagonists.",[170],{"source":33,"section":171},"4",[173,180],{"text":174,"refs":177},{"fa":175,"en":176},"عوارض دستگاه عصبی مرکزی (به‌ویژه در نارسایی کلیه)","Central nervous system adverse reactions",[178],{"source":33,"section":179},"5.1",{"text":181,"refs":184},{"fa":182,"en":183},"پاسخ علامتی، بدخیمی معده را رد نمی‌کند","Symptomatic response does not rule out gastric malignancy",[185],{"source":33,"section":186},"5.2",[188],{"egfrBelow":189,"severity":190,"text":191,"refs":194},60,"warn",{"fa":192,"en":193},"دوز بی‌خطر در کودکان با نارسایی کلیه تعیین نشده است؛ در بزرگسالان کلیرانس کمتر از ۶۰ طبق جدول ۳ کاهش یابد.","No safe dose established in pediatric renal impairment; adults with CrCl \u003C60 per Table 3.",[195],{"source":33,"section":196},"2.3",[],[],{"status":200,"reviewer":201,"date":201},"unverified",null,[203,208,211,217,222,225,230,235],{"regimen":37,"formulation":22,"input":204,"expect":205},{"ageYears":29,"weightKg":140},{"perDose":206,"mlPerDose":207,"upperPerDose":140},10,1.25,{"regimen":59,"formulation":22,"input":209,"expect":210},{"ageYears":29,"weightKg":140},{"perDose":29,"upperPerDose":206},{"regimen":74,"formulation":22,"input":212,"expect":215},{"ageDays":213,"weightKg":214},30,4,{"perDose":67,"mlPerDose":216,"upperPerDose":214},0.25,{"regimen":94,"formulation":22,"input":218,"expect":221},{"ageMonths":219,"weightKg":220},6,8,{"perDose":214,"upperPerDose":220,"mlPerDose":49},{"regimen":115,"formulation":22,"input":223,"expect":224},{"ageYears":29,"weightKg":140},{"perDose":206,"mlPerDose":207},{"regimen":115,"formulation":22,"input":226,"expect":229},{"ageYears":227,"weightKg":228},15,90,{"perDose":27},{"regimen":132,"formulation":22,"input":231,"expect":233},{"ageYears":213,"weightKg":232},70,{"perDose":140,"mlPerDose":234},2.5,{"regimen":146,"formulation":22,"input":236,"expect":237},{"ageYears":213,"weightKg":232},{"perDose":27,"mlPerDose":29},[239],"A02BA03",{"status":241,"forms":242,"refs":263},"registered",[243,247,251,255,259],{"code":244,"en":245,"fa":246},"00527","FAMOTIDINE 20MG TAB","قرص فاموتیدین ۲۰ میلی‌گرم",{"code":248,"en":249,"fa":250},"00528","FAMOTIDINE 40MG TAB","قرص فاموتیدین ۴۰ میلی‌گرم",{"code":252,"en":253,"fa":254},"52859","FAMOTIDINE INJECTION, 10 mg\u002F1m 2 ML AMP","آمپول فاموتیدین ۱۰ میلی‌گرم \u002F ۱ M ۲ میلی‌لیتر",{"code":256,"en":257,"fa":258},"53011","FAMOTIDINE POWDER, FOR SUSPENSION ORAL 40 mg\u002F5mL 120M","سوسپانسیون خوراکی فاموتیدین ۴۰ میلی‌گرم \u002F ۵ میلی‌لیتر ۱۲۰ M",{"code":260,"en":261,"fa":262},"53000","FAMOTIDINE POWDER, FOR SUSPENSION ORAL 40 mg\u002F5mL 50 mL","سوسپانسیون خوراکی فاموتیدین ۴۰ میلی‌گرم \u002F ۵ میلی‌لیتر ۵۰ میلی‌لیتر",[264],{"source":265,"section":266,"url":267},"darooyab-generic","G-2584\u002FFamotidine","https:\u002F\u002Fwww.darooyab.ir\u002FG-2584\u002FFamotidine",[269,273,277,280,283,286],{"kind":270,"url":271,"label":272},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=219091","ANDA219091",{"kind":274,"url":275,"label":276},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=4af90b5d-f47a-4436-8e24-4cb7e5b758b3","FDA Famotidine susp",{"kind":278,"url":279,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa687011.html",{"kind":278,"url":281,"label":282},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601142.html","Famotidine Injection",{"kind":284,"url":285,"label":239},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A02BA03",{"kind":287,"url":267,"label":8},"darooyab",{"pregnancy":289,"lactation":298,"pediatric":306,"geriatric":314},{"level":290,"text":291,"quote":294,"refs":295},"caution",{"fa":292,"en":293},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data with H 2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",[296],{"source":33,"section":297},"8.1",{"level":290,"text":299,"quote":302,"refs":303},{"fa":300,"en":301},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are limited data available on the presence of famotidine in human breast milk.",[304],{"source":33,"section":305},"8.2",{"level":290,"text":307,"quote":310,"refs":311},{"fa":308,"en":309},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Peptic Ulcer Disease and GERD With or Without Esophagitis and Ulcerations Pediatric Patients 1 Year to Less Than 17 Years of Age The safety and effectiveness of famotidine for oral suspension have been established in pediatric patients 1 year to less than 17 years of age for the treatment of peptic ulcer disease and …",[312],{"source":33,"section":313},"8.4",{"level":290,"text":315,"quote":318,"refs":319},{"fa":316,"en":317},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In postmarketing experience, CNS adverse reactions have been reported in elderly patients with and without renal impairment receiving famotidine [see Warnings and Precautions (5.1) ] .",[320],{"source":33,"section":321},"8.5",{"kind":323,"refs":324,"id":272},"ANDA",[325],{"source":33,"section":326},"SPL approval \u002F marketing category",1792440719919]